ALBERT

All Library Books, journals and Electronic Records Telegrafenberg

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    facet.materialart.
    Unknown
    MDPI - Multidisciplinary Digital Publishing Institute
    Publication Date: 2024-01-08
    Description: Metronomic chemotherapy is now, finally, in clinical use. After 20 years of preclinical development and clinical trials, the emerging data will be of paramount importance in allowing us to assess the impact of metronomic chemotherapy on different tumor types. Indeed, it is likely that the next decade will see a major reassessment of the possible applications of metronomic chemotherapy, both alone and in combination with new therapeutic approaches such as immunotherapies, for the management of cancer. Moreover, the results of clinical trials will likely profoundly affect the direction of the laboratory efforts that are going on in parallel and aiming to improve the personalization of this therapeutic strategy. This Special Issue is our attempt to cover the past and present clinical results that have brought us to this pivotal moment and will form the basis of future clinical developments. Scientists and clinicians caring for cancer patients are well aware of the challenges in dealing with this particular therapeutic approach; one such challenge is obtaining improvements in patient survival without significant toxicity. This edition includes clinical research on chemotherapy and ongoing controversies related to metronomic chemotherapy.
    Keywords: metronomic ; oral cancer ; oral squamous cell carcinoma ; metronomic chemotherapy ; metastatic castration-resistant prostate cancer ; cyclophosphamide ; side effects ; pediatric tumors ; etoposide ; valproic acid ; prostate cancer ; CRPC ; castration ; capecitabine ; paclitaxel ; immunomodulation ; angiogenesis ; microbiome ; breast cancer ; safety ; preclinical studies ; clinical studies ; pharmacokinetic studies ; biomarkers ; chemo-free ; DLBCL ; diffuse-large-b-cell-lymphoma ; elderly ; frail ; comprehensive geriatric assessment ; chemo-endocrine therapy ; FulVEC ; pediatric oncology ; brain tumors ; pharmacology ; medulloblastoma ; ATRT ; immunotherapy ; lymphoma ; vinorelbine ; checkpoint inhibitors ; bic Book Industry Communication::M Medicine
    Language: English
    Format: application/octet-stream
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...